Geoffrey J. Lindeman
#148,399
Most Influential Person Now
Researcher
Geoffrey J. Lindeman's AcademicInfluence.com Rankings
Geoffrey J. Lindemancomputer-science Degrees
Computer Science
#7630
World Rank
#8033
Historical Rank
Computational Linguistics
#1557
World Rank
#1574
Historical Rank
Machine Learning
#2879
World Rank
#2915
Historical Rank
Artificial Intelligence
#3173
World Rank
#3220
Historical Rank
Download Badge
Computer Science
Geoffrey J. Lindeman's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Geoffrey J. Lindeman Influential?
(Suggest an Edit or Addition)Geoffrey J. Lindeman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cancer stem cells in solid tumours: accumulating evidence and unresolved questions (2008) (3396)
- Generation of a functional mammary gland from a single stem cell (2006) (2047)
- Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers (2009) (1339)
- Cancer stem cells: current status and evolving complexities. (2012) (1197)
- Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation (2007) (799)
- Control of mammary stem cell function by steroid hormone signalling (2010) (674)
- An autocrine TGF-β/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition (2011) (477)
- Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. (1994) (473)
- In situ identification of bipotent stem cells in the mammary gland (2014) (469)
- Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. (2008) (441)
- Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways (2010) (401)
- Breast-cancer risk in families with mutations in PALB2. (2014) (367)
- The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. (2008) (332)
- E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. (2000) (316)
- Steroid hormone receptor status of mouse mammary stem cells. (2006) (304)
- Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. (2013) (255)
- The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. (2000) (245)
- Patient-derived xenograft models of breast cancer and their predictive power (2015) (237)
- Differential hypermethylation of SOCS genes in ovarian and breast carcinomas (2004) (226)
- The Ets transcription factor Elf5 specifies mammary alveolar cell fate. (2008) (223)
- Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study (2014) (222)
- RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers (2016) (217)
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer (2017) (213)
- The subcellular localization of E2F-4 is cell-cycle dependent. (1997) (213)
- A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting. (1998) (204)
- Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer (2013) (182)
- Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 (2011) (175)
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (166)
- Socs2 and elf5 mediate prolactin-induced mammary gland development. (2006) (163)
- Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource (2006) (163)
- The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 Activity* (2002) (157)
- The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer (2001) (145)
- Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer (2017) (140)
- Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling (2017) (137)
- Elf5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation (2005) (135)
- Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers (2019) (129)
- E2F4 Is Exported from the Nucleus in a CRM1-Dependent Manner (2001) (126)
- Defective Neural Tube Closure and Anteroposterior Patterning in Mice Lacking the LIM Protein LMO4 or Its Interacting Partner Deaf-1 (2004) (123)
- Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. (2003) (119)
- Global changes in the mammary epigenome are induced by hormonal cues and coordinated by Ezh2. (2013) (119)
- Resident macrophages influence stem cell activity in the mammary gland (2009) (118)
- Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer (2016) (111)
- Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14 (2011) (110)
- Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. (2020) (106)
- Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study (2011) (104)
- SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. (2001) (103)
- Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. (2019) (94)
- Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. (2005) (94)
- Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive (2017) (89)
- The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine (2010) (89)
- Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. (2017) (88)
- StarD10, a START Domain Protein Overexpressed in Breast Cancer, Functions as a Phospholipid Transfer Protein*[boxs] (2005) (85)
- Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer (2019) (84)
- Mammary stem cells and mammopoiesis. (2006) (83)
- Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. (2009) (81)
- Derivation of a robust mouse mammary organoid system for studying tissue dynamics (2017) (81)
- Aldehyde Dehydrogenase Activity Is a Biomarker of Primitive Normal Human Mammary Luminal Cells (2012) (80)
- A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer. (2018) (80)
- Risk‐reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study (2006) (75)
- A single‐cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast (2021) (74)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
- Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. (2010) (72)
- XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland (2005) (72)
- Modeling breast cancer using CRISPR/Cas9-mediated engineering of human breast organoids. (2019) (71)
- A role for common genomic variants in the assessment of familial breast cancer. (2012) (71)
- Isolation of Mouse Mammary Epithelial Subpopulations: A Comparison of Leading Methods (2012) (71)
- Essential role for a novel population of binucleated mammary epithelial cells in lactation (2016) (70)
- Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling (2020) (69)
- EGF-mediated induction of Mcl-1 at the switch to lactation is essential for alveolar cell survival (2015) (64)
- Insights into the cell of origin in breast cancer and breast cancer stem cells (2010) (62)
- Transcriptional regulators in mammary gland development and cancer. (2003) (62)
- The mammary stem cell hierarchy. (2014) (58)
- CPAP is a novel stat5-interacting cofactor that augments stat5-mediated transcriptional activity. (2002) (58)
- Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
- c‐myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3 (2006) (57)
- Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region (2003) (55)
- Dimerization of CtIP, a BRCA1- and CtBP-interacting Protein, Is Mediated by an N-terminal Coiled-coil Motif* (2004) (54)
- Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays? (2011) (54)
- Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma (2018) (53)
- Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients (2012) (53)
- Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort (2004) (52)
- Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer (2005) (50)
- Knocking Off SOCS Genes in the Mammary Gland (2007) (48)
- Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants (2005) (47)
- Grhl3 and Lmo4 play coordinate roles in epidermal migration. (2008) (47)
- Delineating the epithelial hierarchy in the mouse mammary gland. (2008) (46)
- The Emerging Picture of the Mouse Mammary Stem Cell (2007) (46)
- The LIM Domain Protein Lmo4 Is Highly Expressed in Proliferating Mouse Epithelial Tissues (2005) (44)
- Spotlight on the utility of the Oncotype DX® breast cancer assay (2018) (44)
- Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake. (2007) (43)
- Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer (2019) (42)
- Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. (1995) (42)
- Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer (2020) (42)
- Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:ψBRCA1 recombination (2002) (41)
- Distinct nuclear receptor expression in stroma adjacent to breast tumors (2013) (40)
- The Phosphoprotein StarD10 Is Overexpressed in Breast Cancer and Cooperates with ErbB Receptors in Cellular Transformation (2004) (39)
- Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells (2020) (36)
- Design, production and characterization of FLIN2 and FLIN4: the engineering of intramolecular ldb1:LMO complexes. (2001) (34)
- Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits (2015) (34)
- Proteomic profiling of secretome and adherent plasma membranes from distinct mammary epithelial cell subpopulations (2011) (33)
- Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2 (2014) (33)
- The Molecular Culprits Underlying Precocious Mammary Gland Involution (2007) (33)
- Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome. (2004) (33)
- Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors (2008) (33)
- Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer. (2009) (32)
- Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men (2013) (32)
- Analysis of hematopoiesis in max 41 transgenic mice that exhibit sustained elevations of blood granulocytes and monocytes. (1995) (32)
- B-lymphoid to granulocytic switch during hematopoiesis in a transgenic mouse strain. (1994) (32)
- Stem cells and cancer – The promise and puzzles (2010) (31)
- The Angelina Jolie effect (2013) (31)
- Deaf-1 regulates epithelial cell proliferation and side-branching in the mammary gland (2008) (31)
- Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma (2008) (31)
- Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development (2005) (30)
- Nipple aspiration and ductal lavage in women with a germline BRCA1 or BRCA2 mutation (2005) (30)
- Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary (2014) (30)
- A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1 (2015) (29)
- Out-RANKing BRCA1 in Mutation Carriers. (2017) (29)
- Lineage Enforcement by Inductive Mesenchyme on Adult Epithelial Stem Cells across Developmental Germ Layers (2009) (29)
- Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers (2010) (29)
- The complexities and caveats of lineage tracing in the mammary gland (2016) (27)
- Threonine 391 Phosphorylation of the Human Prolactin Receptor Mediates a Novel Interaction with 14-3-3 Proteins* (2003) (27)
- Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. (2011) (26)
- Accuracy and completeness in reporting family history of prostate cancer by unaffected men. (2004) (26)
- Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit (2011) (26)
- BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer (2008) (25)
- Tumour morphology predicts PALB2 germline mutation status (2013) (25)
- Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features (2015) (24)
- Targeting triple-negative breast cancers with the Smac-mimetic birinapant (2020) (24)
- Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment (2017) (24)
- A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study (2021) (24)
- The unmasking of novel unipotent stem cells in the mammary gland (2011) (23)
- Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients (2012) (23)
- New Monoclonal Antibodies to Defined Cell Surface Proteins on Human Pluripotent Stem Cells (2017) (21)
- Mutational analysis of the LMO4 gene, encoding a BRCA1‐interacting protein, in breast carcinomas (2003) (21)
- Foxp1 Is Indispensable for Ductal Morphogenesis and Controls the Exit of Mammary Stem Cells from Quiescence. (2018) (21)
- “Cancer in the family” and genetic testing: implications for life insurance (2003) (21)
- Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status (2010) (19)
- Cell fate takes a slug in BRCA1-associated breast cancer (2011) (19)
- Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). (2021) (19)
- Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. (2008) (18)
- Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (2018) (17)
- Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? (2014) (17)
- Characterization of the breast cancer associated ATM 7271T>G (V2424G) mutation by gene expression profiling (2006) (17)
- Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis (2020) (17)
- The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: Current status and future directions (2011) (16)
- Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response (2019) (16)
- Intravital microscopy of dynamic single-cell behavior in mouse mammary tissue (2021) (16)
- Frequency of the ATM IVS10-6T→G variant in Australian multiple-case breast cancer families (2004) (16)
- The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia (2013) (16)
- Intraclonal Plasticity in Mammary Tumors Revealed through Large-Scale Single-Cell Resolution 3D Imaging. (2019) (15)
- Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. (2003) (15)
- A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
- Solitary pituitary metastasis from HER2‐positive breast cancer (2017) (15)
- CPAP interacts with 14-3-3 in a cell cycle-dependent manner. (2006) (14)
- The future of mammary stem cell biology: the power of in vivo transplants (2008) (13)
- Intravenous or oral adjuvant CMF for node-positive breast cancer. (1992) (12)
- Triple‐negative breast cancer: making the most of a misnomer (2012) (12)
- Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer (2019) (12)
- The beliefs, and reported and intended behaviors of unaffected men in response to their family history of prostate cancer (2008) (11)
- RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. (2017) (11)
- Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids (2018) (10)
- Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics (2019) (10)
- Elf 5 is essential for early embryogenesis and mammary gland development during pregnancy and lactation (2005) (10)
- Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis (2021) (10)
- LMO4 expression in squamous cell carcinoma of the anterior tongue (2011) (10)
- Genetic services for men: The preferences of men with a family history of prostate cancer (2006) (10)
- Single cell transcriptome atlas of mouse mammary epithelial cells across development (2021) (9)
- Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics (2020) (9)
- MACROPHAGES, MORE THAN JUST SCAVENGERS: THEIR ROLE IN BREAST DEVELOPMENT AND CANCER (2008) (9)
- Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history. (2017) (8)
- Targeting BCL-2 in breast cancer: exploiting a tumor lifeline to deliver a mortal blow? (2013) (8)
- EXPRESSION OF S100A2 CALCIUM-BINDING PROTEIN PREDICTS RESPONSE TO PANCREATECTOMY FOR PANCREATIC CANCER (2008) (7)
- Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study. (2017) (7)
- Breast cancer protein StarD10 identified by three‐dimensional separation using free‐flow electrophoresis, reversed‐phase high‐performance liquid chromatography, and sodium dodecyl sulfate‐polyacrylamide gel electrophoresis (2005) (7)
- MMTV-trBrca1 mice display strain-dependent abnormalities in vaginal development. (2004) (7)
- Cyclin D1 as the putative bcl-1 oncogene. (1995) (6)
- VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results (2022) (6)
- Frequent activating STAT 3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma (2018) (6)
- Novel p53 germline mutation in a patient with Li−Fraumeni syndrome (2003) (6)
- Hereditary Breast Cancer Genetics—From Clinical Curiosities to Mainstream Paradigms (2011) (5)
- Management of testicular seminoma at Westmead Hospital from 1980 to 87. (1991) (5)
- Breast cancer risk and the BRCA1 interacting protein CTIP (2008) (5)
- Abstract CT101: D-BEYOND: A window of opportunity trial evaluating denosumab, a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2018) (5)
- EpCAM and solid tumour fractionation (2009) (5)
- The role of bipedal lymphangiography in testicular seminoma. (1990) (4)
- Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation (2021) (4)
- Prostate screening uptake in Australian BRCA1 and BRCA2 carriers (2007) (4)
- Breast conservation versus mastectomy in triple-negative breast cancer: two steps forward, one step back? (2011) (4)
- Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2–positive metastatic breast cancer (MBC) (2019) (4)
- PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. (2022) (4)
- Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result (2019) (3)
- A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1 (2015) (3)
- Abstract P4-04-03: Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveals Multiple Conserved Genes and Pathways (2010) (3)
- Cancer risk management practices of non-carriers within BRCA1/2 mutation positive families in the Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab). (2006) (3)
- Mammary stem cells and their regulation by steroid hormones (2011) (3)
- Targeting triple-negative breast cancers with the Smac-mimetic birinapant (2020) (2)
- Impaired lactation in mice expressing dominant‐negative FADD in mammary epithelium (2009) (2)
- Construction of developmental lineage relationships in the mouse mammary gland by single-cell RNA profiling (2017) (2)
- Shedding Light on Mammary Stem Cells and Tumorigenesis (2006) (2)
- R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue (2022) (2)
- Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors (2021) (2)
- Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA. (2019) (2)
- Abstract S5-6: Steroid Hormone Regulation of Mammary Stem Cell Function (2010) (2)
- Abstract PL04-02: The breast epithelial hierarchy and its implications for tumor heterogeneity (2014) (2)
- Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation (2020) (2)
- Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (2018) (2)
- Targeting the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts: Microtubule polymerisation inhibitors. (2015) (1)
- Abstract OT-28-03: VICKI: A Phase Ib/II, randomized, placebo-controlled, study of venetoclax plus ado-trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC) (2021) (1)
- Mammary Stem Cells (2007) (1)
- Expression of LMO 4 and outcome in pancreatic ductal adenocarcinoma (2008) (1)
- Outcomes of women at high familial risk for breast cancer: An 8‐year single‐center experience (2020) (1)
- In vivo genome‐editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis (2021) (1)
- Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation (2020) (1)
- Deciphering breast cancer: from biology to the clinic (2023) (1)
- Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (1)
- Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care (2023) (1)
- Complementary and alternative medicine (CAM) use in high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) (2008) (1)
- Abstract PD7-07: Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer (2019) (1)
- Letter The future of mammary stem cell biology: the power of in vivo (2008) (1)
- Universal genetic testing of patients with newly diagnosed breast cancer — ready for prime time? (2021) (1)
- Patient-derived xenograft models of breast cancer and their predictive power (2015) (1)
- Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer (2019) (1)
- Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer (2019) (1)
- Abstract OT-27-01: PALVEN: A phase 1b study of palbociclib, letrozole and venetoclax in estrogen receptor, BCL2-positive metastatic breast cancer (2021) (1)
- Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer (2019) (1)
- Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer (2013) (1)
- The complexities and caveats of lineage tracing in the mammary gland (2016) (1)
- Heritable DNA methylation marks associated with susceptibility to breast cancer (2018) (1)
- Biological facts on vaccenic acid. 2. (1948) (1)
- Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer (2019) (1)
- Mammography Adherence among High-Risk Women with Breast Cancer and Either a Non-Pathogenic Mutation Identified or Untested BRCA1/2 Genetic Status (2020) (1)
- Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers. (2009) (1)
- Abstract P5-03-02: Expression of RANK and RANK ligand (RANKL) in breast carcinoma and distinct breast epithelial cells from BRCA1 mutation carriers (2013) (1)
- Abstract S2-04: RANK ligand as a target for breast cancer prevention inBRCA1mutation carriers (2017) (1)
- Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits (2015) (1)
- P3-16-08: A Phase 2, Randomized Open-Label Study of Iniparib, Administered Either Weekly or Twice-Weekly in Combination with Gemcitabine Plus Carboplatin in Patients with mTNBC. (2011) (0)
- The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer (2019) (0)
- Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer (2013) (0)
- Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis (2012) (0)
- Single cell transcriptome atlas of mouse mammary epithelial cells across development (2021) (0)
- Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics (2020) (0)
- Outcomes of women at high familial risk for breast cancer in Australia: An 8-year single-centre experience. (2019) (0)
- Common genomic variants associated with breast cancer predict the risk of second primary breast cancer diagnosis (2012) (0)
- Expression of the interleukin-3/receptor complex by breast cancer cells promotes vascular mimicry via a PI3K-dependent mechanism and is associated with poor outcome (2019) (0)
- Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result (2019) (0)
- Improving the provision of Melbourne Health Familial Cancer services to Victoria’s Culturally and Linguistically Diverse (CALD) communities (2012) (0)
- Tuberculous meningitis in adults: practical comments on the diagnosis. (1986) (0)
- Abstract P3-08-08: Preferences for breast cancer risk reduction amongBRCA1andBRCA2mutation carriers: A discrete choice experiment (2017) (0)
- Breast Stem Cells and Their Implications for Cancer (2007) (0)
- PD08-02: Targeting BCL-2 Expressing Breast Tumors with BH3-Mimetics – A New Class of Drugs in Breast Cancer? (2011) (0)
- Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice (2021) (0)
- Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort (2012) (0)
- Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics (2012) (0)
- Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics (2012) (0)
- Improving the provision of Melbourne Health Familial Cancer services to Victoria’s Culturally and Linguistically Diverse (CALD) communities (2012) (0)
- Peer live supervision in the familial cancer setting (2012) (0)
- Familial Cancer 2003 – Research and Practice, Couran Cove, Queensland, Australia, 3–6 September 2003 (2004) (0)
- Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutaion carriers (2008) (0)
- Tissue-resident ductal macrophages survey the mammary epithelium and facilitate tissue remodelling (2020) (0)
- Abstract A035: Role of the transcription factor Id4 in the developing mammary gland (2013) (0)
- Cyclin D1transgene impedes lymphocyte maturation andcollaborates inlymphomagenesis withthemyc gene (1994) (0)
- Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
- Triple negative breast cancer: proven and promising systemic therapies (2016) (0)
- Abstract IA02: Mapping stem and progenitor cells to decipher the origins of breast cancer (2018) (0)
- An Introduction to ICCon - Inherited Cancer Connect Partnership (2013) (0)
- CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (0)
- The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort (2012) (0)
- Predicting breast cancer risk in BRCA1 and BRCA2 carriers: Methylation studies using intraductal fluid (2007) (0)
- novel interaction with 14-3-3 proteins (2003) (0)
- PG 7.02 BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer? (2015) (0)
- Breast Stem Cell Markers and Tumor Stem Cells in BRCA1, BRCA2 and Non-BRCA 1/2 Women (2006) (0)
- The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
- Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer (2019) (0)
- 11th Lorne Cancer Conference, Lorne, Victoria, Australia, 11-14th February 1999. (1999) (0)
- S17 Breast stem and progenitor cells in cancer – Therapeutic implications (2011) (0)
- The Inherited Cancer Connect (ICCON) mutation-carrier database (2014) (0)
- Altered cytokeratin and vimentin expression in mammary epithelial cells with disrupted BRCA1 function (2005) (0)
- Abstract IA12: Mammary epithelial subtypes and their implications for breast cancer (2013) (0)
- Breast-Cancer Risk in Families With Mutations in PALB2 EDITORIAL COMMENT (2014) (0)
- The ICCon familial cancer database (2018) (0)
- Abstract P3-09-02: Mutational assessment of newly diagnosed breast cancer using Germline and tumor genomICs (2022) (0)
- Abstract BL1: Deciphering stem and progenitor cells to understand breast cancer (2020) (0)
- Abstract P6-10-02: Patient rather than physician-related barriers to tamoxifen uptake for breast cancer prevention in high-risk women (2016) (0)
- Abstract P3-11-05: RANK ligand is a target for breast cancer prevention inBRCA1mutation carriers (2016) (0)
- Abstract IA19: Targeting the BCL-2 family in breast cancer (2016) (0)
- Prostate Cancer Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA 2 Mutation Carriers (2019) (0)
- Abstract SY10-04: Delineating cellular targets of transformation in breast cancer (2012) (0)
- Risk management practices of Australasian BRCA1 and BRCA2 mutation carriers (2006) (0)
- Contribution of the Cyclin D1 Gene to Lymphomagenesis (1995) (0)
- Abstract 5024: Unmasking heterogeneity within the adult mammary stem cell compartment (2017) (0)
- Abstract TS3-1: Beyond B cells: Targeting BCL-2 pro-survival proteins in breast cancer (2019) (0)
- A phase 3 study to determine the breast cancer risk reducing effect of denosumab in women carrying a germline BRCA1 mutation (BRCA-P Study). (2022) (0)
- Abstract PD5-06: The immunomodulatory potential of denosumab in breast cancer: results from D-BEYOND, a window of opportunity trial evaluating a RANK-ligand (RANKL) inhibitor and its biological effects in young pre-menopausal women diagnosed with early breast cancer (2019) (0)
- R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue (2022) (0)
- Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features (2015) (0)
- Peer live supervision in the familial cancer setting (2012) (0)
- R code and downstream analysis objects for the scRNA-seq atlas of human breast spanning normal, preneoplastic and tumorigenic states (2021) (0)
- Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (0)
- Venetoclax treatment in cancer patients has limited impact on circulating T and NK cells. (2022) (0)
- Identification of Taxreb107 as a lactogenic hormone responsive gene in mammary epithelial cells. (2003) (0)
- The LIM domain gene LMO4 is overexpressed in breast cancer and forms a complex with the tumor suppressor BRCA1 (2002) (0)
- The impact of coding germline variants on contralateral breast cancer risk and survival (2023) (0)
- Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA). (2017) (0)
- Review of: A putative human breast stem cell population is enriched for steroid receptor-positive cells (2005) (0)
- Abstract BSF1-2: Understanding Stem Cells To Get Abreast of Breast Cancer (2010) (0)
- Abstract P5-13-06: Exploratory biomarker analysis in VERONICA, a phase 2 study of venetoclax + fulvestrant versus fulvestrant in patients with estrogen receptor (ER)-positive HER2-negative metastatic breast cancer (mBC) (2022) (0)
- Outclassing kath and kim an aussie kith and kin cancer conference: Meeting report on "Familial Cancer 2003 - Research and Practice", Couran Cove, Queensland, September 2003 (2003) (0)
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
- A role for BRCA1 in mammary epithelial morphogenesis, differentiation and adhesion (2002) (0)
- The incidence of PALB2 c.3113G>A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia (2013) (0)
- Abstract SY12-03: Getting abreast of the mammary epithelial hierarchy and breast cancer (2011) (0)
- Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018) (2018) (0)
- OP0024 Use of novel patient-derived xenografts and molecular subtyping to improve precision medicine in high-grade serous ovarian cancer (2014) (0)
- Abstract OT1-01-03: The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Geoffrey J. Lindeman?
Geoffrey J. Lindeman is affiliated with the following schools:
